Sökning: "malignancies"
Visar resultat 16 - 20 av 492 avhandlingar innehållade ordet malignancies.
16. CD19-targeting CAR T Cells for Treatment of B Cell Malignancies : From Bench to Bedside
Sammanfattning : Immunotherapy for cancer is a young research field progressing at high speed. The first chimera of an antibody and a signaling chain was designed by Zelig Eshhar and was later further developed to enhance existing T cell therapy by combining a single-chain fragment of an antibody with the CD3 zeta chain of the TCR complex. LÄS MER
17. Multiple primary malignancies in breast cancer patients. From population study to genetics
Sammanfattning : Breast cancer (BC) is one of the most common causes of cancer-related death among women worldwide. Due to early detection of BC and more tailor-made treatments, patients live longer despite their illness. Studies have shown that BC patients are at risk of developing new tumors in organs other than the breast, mainly caused by BC treatment. LÄS MER
18. Inverted papilloma and sinonasal malignancies in Sweden
Sammanfattning : Background: Sinonasal malignancies (SNMs) are rare and in Sweden they account for approximately 0,1% of all malignancies and 5% of all head and neck malignancies. Apart from sinonasal malignant melanoma (SNMM), their incidence has been reported to decrease since 1960 while the survival rates have remained rather stable during the same time-period. LÄS MER
19. Bloodstream infections in patients with hematological malignancies
Sammanfattning : Patients with hematological malignancies have an increased risk of infectious complications. These complications can be caused by disease-specific factors or be treatment-related. Bloodstream infections increase the risk of morbidity, mortality, have a negative impact on quality of life, and may lead to reductions in treatment intensity. LÄS MER
20. Real-world studies on B-cell malignancies
Sammanfattning : Randomized controlled trials remain the preferred way of evaluating new treatments. However, in studies on malignancies, trial data may not always be sufficient to address the requirements of health care providers and regulatory agencies regarding recommendations as patients are strictly selected through inclusion- and exclusion criteria. LÄS MER